If you have been reading about actin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-29. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
1993/1445) Trade Effluent (Asbestos) (Scotland) Regulations 1993 (S.I. 1993/1446) Parking Attendants (Wearing of Uniforms) (London) Regulations 1993 (S.I. 1993/1450) Harbour Authorities (Variation of Constitution) Order 1993 (S.I. 1993/1451) Housing Renovation etc. Grants (Prescribed Forms and Particulars) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1452) County Council of Clwyd (A525 St Asaph—Rhyl Road, Rhuddlan Bypass Stage II) River Clwyd Bridge Scheme 1992 Confirmation Instrument 1993 (S.I. 1993/1456) Building Standards (Scotland) Amendment Regulations 1993 (S.I. 1993/1457) Borders Region (Electoral Arrangements) Order 1993 (S.I. 1993/1458) Road Traffic Act 1991 (Commencement No. 6 and Transitional Provisions) Order 1993 (S.I. 1993/1461) Hoole Island Junction (M53/A56) Chester (Detrunking) Order 1993 (S.I. 1993/1462) Road Traffic (Special Parking Areas) (The London Borough of Wandsworth) Order 1993 (S.I. 1993/1474) Removal and Disposal of Vehicles (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1475) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No. 3) Order 1993 (S.I. 1993/1476) Plant Health Fees (Scotland) Order 1993 (S.I. 1993/1477) A11 Trunk Road (A505 Junction to Four Went Ways Improvement and Slip Roads) Order 1993 (S.I. 1993/1478) A11 Trunk Road (A505 Junction to Four Went Ways) (Detrunking) Order 1993 (S.I. 1993/1479) Council Tax Limitation (England) (Maximum Amounts) Order 1993 (S.I. 1993/1480) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No.4) Order 1993 (S.I.
Potassium alum crystallizes in regular octahedra with flattened corners and is very soluble in water. The solution is slightly acidic and is astringent to the taste. Neutralizing a solution of alum with potassium hydroxide will begin to cause the separation of Al(OH)3, which redissolves with excess hydroxide. When heated to nearly a red heat, it gives a porous, friable mass, which is known as "burnt alum". It fuses at 92 °C (198 °F) in its own water of crystallization.
Lysergic acid methylpropylamide (LAMPA, LAMP, or LMP), also known as LMP-55 or as N-methyl-N-propyllysergamide (MPLA), is a structural analogue of lysergic acid diethylamide (LSD) that has been studied as a potential treatment for alcoholism. In animal studies, LAMPA was found to be nearly equipotent to ECPLA and MIPLA for inducing a head-twitch response. LAMPA appears to be significantly less potent than LSD in humans, producing little to no noticeable effects at doses of 100 μg. It shows reduced-efficacy partial agonism of the serotonin 5-HT2A receptor relative to LSD, which may be responsible for its equivocal hallucinogenic effects. LAMPA is not an explicitly controlled substance in the United States, but may be considered implicitly controlled as it is an isomer of LSD. The drug is not a controlled substance in Canada as of 2025.
Triple-decker complexes are composed of three Cp anions and two metal cations in alternating order. The first triple-decker sandwich complex, [Ni2Cp3]+, was reported in 1972. Many examples have been reported subsequently, often with boron-containing rings.
It is the most active antagonist known of silk moth (Bombyx mori) octopamine receptor α, intermediate for Bm tyramine receptors 1 & 2, weak for Drosophila octopamine receptor β, high for Drosophila tyramine receptor 1, intermediate for migratory locust (Locusta migratoria) tyramine receptor 1, and high for American cockroach (Periplaneta americana) octopamine receptor α and tyramine receptor 1.
Sources: en.wikipedia.org
18 July A survey of more than 3,000 experts finds that the extinction crisis could be worse than previously thought, and estimates that roughly 30% of species "have been globally threatened or driven extinct since the year 1500." The first "dormant" black hole (meaning it does not emit high levels of X-ray radiation) is identified outside the Milky Way. The object, with nine solar masses, orbits a rare O-type star in a system called VFTS 243 within the Large Magellanic Cloud. A study shows that climate change-related exceptional marine heatwaves in the Mediterranean Sea during 2015–2019 resulted in widespread mass sealife die-offs in five consecutive years. 20 July – Scientists report that SARS-CoV-2 builds tunneling nanotubes from nose cells to gain access to the brain. 21 July A potential gene therapy cure for haemophilia B, which corrects the genetic defect associated with the condition is announced with trial results by doctors. It caused a sustained increase in factor IX activity in 9 of 10 patients in the small trial. Sunspot AR3060 explodes early in the morning. It releases a C-5 class solar flare, and a "solar tsunami". The NOAA predicts that a geomagnetic storm from this event will strike the Earth on 23 July, between 0000 UTC and 0400 UTC, as a G2 class storm, with a slight chance of a G3 storm. Aurorae could be visible as far south as 50° N latitude. Researchers report the development of deep learning software that can design proteins that contain prespecified functional sites.
== Advances in step-growth polymers == The driving force in designing new polymers is the prospect of replacing other materials of construction, especially metals, by using lightweight and heat-resistant polymers. The advantages of lightweight polymers include high strength and resistance to solvent and other chemicals, contributing to a variety of potential uses, such as electrical and engine parts on automotive and aircraft components, coatings on cookware, coatings and circuit boards for electronic and microelectronic devices, etc. Polymer chains based on aromatic rings are desirable due to high bond strengths and rigid polymer chains. High molecular weight and crosslinking are desirable for the same reason. Strong dipole-dipole interactions, hydrogen bonds, and crystallinity also improve heat resistance. To obtain desired mechanical strength, sufficiently high molecular weights are necessary, however, decreased solubility is a problem. One approach to solve this problem is to introduce of some flexibilizing linkages, such as isopropylidene, C=O, and SO2 into the rigid polymer chain by using an appropriate monomer or comonomer. Another approach involves the synthesis of reactive telechelic oligomers containing functional end-groups capable of reacting with each other; polymerization of the oligomer gives higher molecular weight, referred to as chain extension.
=== Age === Old age is often accompanied by muscular and neurological loss of muscle tone in the upper airway. Decreased muscle tone is also temporarily caused by chemical depressants; alcoholic drinks and sedative medications are the most common. Permanent premature muscular tonal loss in the upper airway may be precipitated by traumatic brain injury, neuromuscular disorders, or poor adherence to chemical and or speech therapy treatments.
LGD-4033, also known by the developmental code name VK5211 and by the black-market name Ligandrol, is a selective androgen receptor modulator (SARM) which is under development for the treatment of muscle atrophy in people with hip fracture. It was also under development for the treatment of cachexia, hypogonadism, and osteoporosis, but development for these indications was discontinued. LGD-4033 has been reported to dose-dependently improve lean body mass and muscle strength in preliminary clinical trials, but is still being developed and has not been approved for medical use. The drug is taken by mouth. Known possible side effects of LGD-4033 include headache, dry mouth, adverse lipid changes like decreased high-density lipoprotein (HDL) cholesterol levels, changes in sex hormone concentrations like decreased testosterone levels, elevated liver enzymes, and liver toxicity. The potential of LGD-4033 and other SARMs for producing masculinization is largely uncharacterized and hence is unknown. LGD-4033 is a nonsteroidal SARM, acting as an agonist of the androgen receptor (AR), the biological target of androgens and anabolic steroids like testosterone and dihydrotestosterone (DHT). However, it shows dissociation of effect between tissues in preclinical studies, with agonistic and anabolic effects in muscle and bone and partially agonistic or antagonistic effects in the prostate gland. LGD-4033 was first described in 2010. It is less clinically studied than other SARMs like enobosarm, with only a few small clinical trials having been conducted and reported.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.